06/01/2026
The FDA has approved the inhaled human insulin Afrezza (MannKind) for children aged 6 years or older with type 1 diabetes (T1D) or type 2 diabetes (T2D).
The product comprises a small inhaler device that delivers the insulin formulation into the bloodstream through the lungs, enabling rapid absorption into the systemic circulation with a short duration. The drug delivery platform, called Technosphere, is designed to be used immediately prior to meals. It does not replace basal insulin for people with T1D. https://mdsc.pe/4wWzTOl